No connection

Search Results

CPHI vs UNH

CPHI
China Pharma Holdings, Inc.
BEARISH
Price
$0.63
Market Cap
$25.5M
Sector
Healthcare
AI Confidence
95%
UNH
UnitedHealth Group Incorporated
NEUTRAL
Price
$323.48
Market Cap
$293.61B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
CPHI
--
UNH
24.43
Forward P/E
CPHI
--
UNH
16.08
P/B Ratio
CPHI
0.43
UNH
3.11
P/S Ratio
CPHI
6.15
UNH
0.66
EV/EBITDA
CPHI
-18.34
UNH
16.47

Profitability

Gross Margin
CPHI
-3.18%
UNH
18.53%
Operating Margin
CPHI
-97.86%
UNH
0.34%
Profit Margin
CPHI
-76.92%
UNH
2.69%
ROE
CPHI
-20.91%
UNH
12.54%
ROA
CPHI
-8.41%
UNH
3.9%

Growth

Revenue Growth
CPHI
8.1%
UNH
12.3%
Earnings Growth
CPHI
--
UNH
-99.9%

Financial Health

Debt/Equity
CPHI
0.17
UNH
0.82
Current Ratio
CPHI
0.32
UNH
0.79
Quick Ratio
CPHI
0.09
UNH
0.7

Dividends

Dividend Yield
CPHI
--
UNH
2.73%
Payout Ratio
CPHI
0.0%
UNH
65.99%

AI Verdict

CPHI BEARISH

CPHI exhibits severe financial distress, anchored by a weak Piotroski F-Score of 2/9 and a critical liquidity crisis. The company is operating with a negative gross margin (-3.18%), meaning it loses money on every product sold before operating expenses are even considered. With a current ratio of 0.32 and a quick ratio of 0.09, the firm lacks the liquid assets to cover its short-term obligations. This fundamental collapse is reflected in a catastrophic 5-year price decline of 99.8%.

Strengths
Low Debt/Equity ratio (0.17) suggests limited long-term leverage
Modest year-over-year revenue growth of 8.10%
Trading at a discount to book value (P/B 0.43)
Risks
Critical liquidity risk with a Current Ratio of 0.32
Negative gross margins indicate a non-viable core business model
Severe profitability collapse (Operating Margin -97.86%)
UNH NEUTRAL

UnitedHealth Group presents a conflicted profile with a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between current price ($323.48) and defensive fair value (Graham Number: $175.91). While revenue growth remains robust at 12.3%, the company has suffered a catastrophic collapse in YoY earnings growth (-99.9%), suggesting severe short-term headwinds or one-time accounting shocks. Technical trends are currently bearish (0/100), though a recent one-month bounce and a favorable Forward P/E of 16.08 indicate analyst expectations of a recovery. The stock is currently trading at a significant premium to its intrinsic value, relying heavily on its market dominance and future earnings normalization.

Strengths
Strong consistent revenue growth (12.3% YoY)
Manageable Debt/Equity ratio of 0.82
Attractive Forward P/E (16.08) compared to current P/E (24.43)
Risks
Extreme earnings volatility (YoY Earnings Growth -99.9%)
Poor liquidity indicated by a Current Ratio of 0.79
Extremely thin operating margins (0.34%)

Compare Another Pair

CPHI vs UNH: Head-to-Head Comparison

This page compares China Pharma Holdings, Inc. (CPHI) and UnitedHealth Group Incorporated (UNH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile